Henry Waxman actually said...

I think this legislation should be narrowly targeted and only apply to antibiotics approved for serious or life-threatening diseases.

I believe that Congress ought to define the problem that you are trying to address.

You don't want to set up an incentive program, in my opinion, that drives developers toward the broadest market.

We must worry not only about patients receiving medications that could be dangerous to them because their safety has not been established in...